139 related articles for article (PubMed ID: 24491303)
1. KRAS and cancer stem cells in APC-mutant colorectal cancer.
Fearon ER; Wicha MS
J Natl Cancer Inst; 2014 Feb; 106(2):djt444. PubMed ID: 24491303
[No Abstract] [Full Text] [Related]
2. Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Cristóbal I; Rincón R; Manso R; Rojo F; García-Foncillas J
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136032
[No Abstract] [Full Text] [Related]
3. Response.
Moon BS; Cho YH; Jeong WJ; Choi KY
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136033
[No Abstract] [Full Text] [Related]
4. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Lee SK; Hwang JH; Choi KY
Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
[TBL] [Abstract][Full Text] [Related]
6. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
[TBL] [Abstract][Full Text] [Related]
7. Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India.
Raman R; Kotapalli V; Adduri R; Gowrishankar S; Bashyam L; Chaudhary A; Vamsy M; Patnaik S; Srinivasulu M; Sastry R; Rao S; Vasala A; Kalidindi N; Pollack J; Murthy S; Bashyam M
Mol Carcinog; 2014 Feb; 53 Suppl 1(0 1):E181-6. PubMed ID: 23168910
[TBL] [Abstract][Full Text] [Related]
8. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.
Obrador-Hevia A; Chin SF; González S; Rees J; Vilardell F; Greenson JK; Cordero D; Moreno V; Caldas C; Capellá G
J Pathol; 2010 May; 221(1):57-67. PubMed ID: 20196079
[TBL] [Abstract][Full Text] [Related]
10. Setting future standards for KRAS testing in colorectal cancer.
van Krieken H; Tol J
Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
[No Abstract] [Full Text] [Related]
11. Wnt and Kras signaling-dark siblings in lung cancer.
Pacheco-Pinedo EC; Morrisey EE
Oncotarget; 2011 Jul; 2(7):569-74. PubMed ID: 21753228
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in primary and metastatic colorectal cancer.
Han CB; Li F; Ma JT; Zou HW
Int J Colorectal Dis; 2013 May; 28(5):731-2. PubMed ID: 22744738
[No Abstract] [Full Text] [Related]
13. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
[No Abstract] [Full Text] [Related]
14. Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas.
Baloglu H; Yigit N
Cancer Lett; 2011 Sep; 308(1):118-21. PubMed ID: 21624768
[TBL] [Abstract][Full Text] [Related]
15. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
[TBL] [Abstract][Full Text] [Related]
16. [Stem cell theory of colorectal cancer and its connection with molecular-biological data].
Hagymási K; Molnár B; Sipos F; Galamb O; Tulassay Z
Orv Hetil; 2007 Apr; 148(17):779-85. PubMed ID: 17452307
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.
Lee SK; Jeong WJ; Cho YH; Cha PH; Yoon JS; Ro EJ; Choi S; Oh JM; Heo Y; Kim H; Min DS; Han G; Lee W; Choi KY
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30413483
[TBL] [Abstract][Full Text] [Related]
18. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
Bass A
J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
[No Abstract] [Full Text] [Related]
19. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
Kawamoto Y; Yoshino T
Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
[No Abstract] [Full Text] [Related]
20. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
